Online citations, reference lists, and bibliographies.

DOI: 10.1002/acr.21772

2012 American College Of Rheumatology Guidelines For Management Of Gout. Part 1: Systematic Nonpharmacologic And Pharmacologic Therapeutic Approaches To Hyperuricemia

D. Khanna, J. Fitzgerald, P. Khanna, S. Bae, M. Singh, T. Neogi, M. Pillinger, J. Merill, S. Lee, Shraddha Prakash, M. Kaldas, Maneesh Gogia, F. Pérez-Ruiz, W. Taylor, F. Lioté, H. Choi, J. Singh, N. Dalbeth, S. Kaplan, V. Niyyar, D. Jones, S. Yarows, B. Roessler, G. Kerr, C. King, G. Levy, D. Furst, N. Edwards, B. Mandell, H. Schumacher, M. Robbins, N. Wenger, R. Terkeltaub

Published 2012 · Medicine

Cite This

Download PDF

Analyze on Scholarcy

Share

DINESH KHANNA, JOHN D. FITZGERALD, PUJA P. KHANNA, SANGMEE BAE, MANJIT K. SINGH, TUHINA NEOGI, MICHAEL H. PILLINGER, JOAN MERILL, SUSAN LEE, SHRADDHA PRAKASH, MARIAN KALDAS, MANEESH GOGIA, FERNANDO PEREZ-RUIZ, WILL TAYLOR, FREDERIC LIOTE, HYON CHOI, JASVINDER A. SINGH, NICOLA DALBETH, SANFORD KAPLAN, VANDANA NIYYAR, DANIELLE JONES, STEVEN A. YAROWS, BLAKE ROESSLER, GAIL KERR, CHARLES KING, GERALD LEVY, DANIEL E. FURST, N. LAWRENCE EDWARDS, BRIAN MANDELL, H. RALPH SCHUMACHER, MARK ROBBINS, NEIL WENGER, AND ROBERT TERKELTAUB

This paper references

10.1136/ard.36.1.80

Multicentre trial of naproxen and phenylbutazone in acute gout.

R. Sturge (1977)

10.1080/15257770.2011.596499

Comorbidities in Patients with Gout

N. Ichikawa (2011)

Sulindac in the treatment of acute gout arthritis.

G. Karachalios (1982)

10.1002/art.27600

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

10.1097/FPC.0b013e3282f3ef9c

A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

Christine Lonjou (2008)

10.1136/ard.62.6.572

Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism

S. Takahashi (2003)

10.1056/NEJMCP030733

Clinical practice. Gout.

R. Terkeltaub (2003)

10.1001/jama.2011.1169

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

J. Sundy (2011)

Gout and its comorbidities.

M. Pillinger (2010)

10.1016/j.annemergmed.2006.11.014

Comparison of Oral Prednisolone/Paracetamol and Oral Indomethacin/Paracetamol Combination Therapy in the Treatment of Acute Goutlike Arthritis: A Double-Blind, Randomized, Controlled Trial

10.6032/GNAM.37.139

American College of Rheumatology guidelines for management of gout

D. Khanna (2013)

Initiating allopurinol therapy: do we need to know the patient’s HLA status

American College of Rheumatology guidelines for management of gout . Part 1 : systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

D Khanna (2012)

the risk of gout in men: prospective cohort study

10.1136/BMJ.J.ISSN.1007-9742.2014.17.140

Roddy Edward (2011)

10.1136/ard.2010.139899

Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide

N. Dalbeth (2011)

Local ice therapy during bouts of acute gouty arthritis.

N. Schlesinger (2002)

10.1136/ard.2010.144063

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

N. Schlesinger (2011)

10.1093/RHEUMATOLOGY/KEM090

Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.

R. Willburger (2007)

Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Gregory C Borstad (2004)

10.1002/art.27327

High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.

R. Terkeltaub (2010)

American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

JA Singh (2012)

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthri

HR Schumacher (2002)

Methodology Perspectives, AHCPR no 95-0009

R. Brook (1994)

[Revised version of Guideline for the Management of Hyperuricemia and Gout].

H. Yamanaka (2008)

NSAID prescribing precautions.

Amanda L. Risser (2009)

10.2165/11205470-000000000-00000

Oral Colchicine (Colcrys®)

10.1136/ard.2006.055269

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)

W. Zhang (2006)

10.3899/jrheum.071229

Quality of Life and Disability in Patients with Treatment-Failure Gout

M. Becker (2009)

10.1080/15257770802136032

Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy

M. Becker (2008)

Gout. Epidemiology of gout

E. Roddy (2010)

Lessons learned from a multiple-dose postoperative analgesic trial. Pain 2004;109:103–9

TR Mendoza (2004)

10.1002/art.33315

Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study.

Mara A McAdams DeMarco (2012)

10.1073/PNAS.0409500102

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

10.1016/j.lpm.2011.02.043

[New therapeutic options for gout].

P. Richette (2011)

update of the 2008 American College of Rheumatology recommendations for the use of disease - modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

JM Grossman (2012)

Clinical guidelines: developing guidelines

PG Shekelle (1999)

10.1185/03007995.2010.533647

Chronic gout: epidemiology, disease progression, treatment and disease burden

R. A. Brook (2010)

10.1016/j.pain.2004.01.015

Lessons learned from a multiple-dose post-operative analgesic trial

T. Mendoza (2004)

10.1185/030079906X112606

The economic burden of gout on an employed population

R. A. Brook (2006)

10.1002/ART.10511

Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.

F. Pérez-Ruiz (2002)

10.1136/annrheumdis-2011-201215

Purine-rich foods intake and recurrent gout attacks

Y. Zhang (2012)

10.1002/art.23721

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Health-related quality of life and outcome measures in gout. In: Terkeltaub, R., editor. Gout and other crystal arthropathies

PP. Khanna (2011)

Systemic corticosteroids for acute gout (Review)

H. Janssens (2008)

10.1136/annrheumdis-2012-201676

Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study

10.1016/0049-0172(90)90070-V

Systemic steroid therapy for acute gout: a clinical trial and review of the literature.

G. D. Groff (1990)

10.1002/acr.21641

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

J. Singh (2012)

10.1136/ard.59.7.539

Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study

P. Dessein (2000)

10.1016/B978-1-4377-2864-4.10018-1

Health-Related Quality of Life and Outcome Measures in Gout

P. Khanna (2012)

10.1093/RHEUMATOLOGY/KEM056A

British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.

K. Jordan (2007)

10.1136/ard.2008.094201

Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography

N. Dalbeth (2009)

10.1136/bmj.324.7352.1488

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

H. R. Schumacher Jr (2002)

10.6133/APJCN.2012.21.2.14

Relationship between dietary patterns and serum uric acid concentrations among ethnic Chinese adults in Taiwan.

10.1016/j.amjopharm.2011.07.004

Management of gout in the older adult.

Michelle A. Fravel (2011)

Methodology perspectives: AHCPR no. 95-0009. Rockville (MD): Public Health Service

10.1161/CIRCULATIONAHA.105.167586

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

M. Becker (2010)

Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study

C. Pineda (2011)

10.1093/ndt/gfr060

HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.

Jae-Woo Jung (2011)

10.1007/s10067-006-0528-3

Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients

M. K. Reinders (2006)

10.1682/JRRD.2006.05.0051

Determining mild, moderate, and severe pain equivalency across pain-intensity tools in nursing home residents.

K. Jones (2007)

10.1002/art.27338

Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort.

Vidula Bhole (2010)

10.1016/j.rdc.2014.01.001

Epidemiology of gout.

E. Roddy (2014)

10.1136/ard.2007.083071

Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol

M. K. Reinders (2009)

10.1002/art.30389

Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors.

R. Terkeltaub (2011)

10.1136/ard.2006.062091

EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

W. Zhang (2007)

The RAND/UCLA Appropriateness Method

R. Brook (1994)

Methodology Perspectives, AHCPR no 95-0009

R. Brook (1994)

10.1097/BOR.0b013e3283438e13

Risk factors for gout and prevention: a systematic review of the literature

J. Singh (2011)

10.1002/art.34488

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

L. Stamp (2012)

10.1002/ART.20405

A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.

A. Shoji (2004)

10.3111/13696998.2010.540874

Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy

N. Edwards (2011)

A survey of current evaluation and treatment of gout.

N. Schlesinger (2006)

American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

G. Rebecca (2011)

10.1097/00000441-198610000-00006

Evaluation of a Thiazide‐Allopurinol Drug Interaction

K. Hande (1986)

10.1002/art.30119

Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.

L. Stamp (2011)

10.1002/art.1780170517

Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients.

H. Paulus (1974)

10.3899/jrheum.110916

Efficacy and Tolerability of Celecoxib in the Treatment of Acute Gouty Arthritis: A Randomized Controlled Trial

H. Schumacher (2012)

10.1016/J.LPM.2011.02.043

Nouveaux traitements de la goutte

P. Richette (2011)

10.1002/art.1780391104

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.

M. Hochberg (2001)

Severe allopurinol hypersensitivity syndrome

G Lupton (1979)

10.1148/rg.315115510

Clinical utility of dual-energy CT for evaluation of tophaceous gout.

Madhura A. Desai (2011)

10.2217/pgs.11.131

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

I. Zineh (2011)

10.1002/art.33369

Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal.

T. Neogi (2012)

10.1097/RHU.0b013e31823e5cda

Assessment of Tophus Size: A Comparison Between Physical Measurement Methods and Dual-Energy Computed Tomography Scanning

N. Dalbeth (2012)

10.1002/ART.20422

Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics.

FDA prescribing information for COLCRYS

10.1002/ART.22014

Gout and the risk of acute myocardial infarction.

E. Krishnan (2006)

10.1136/annrheumdis-2011-200156

Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial

N. Dalbeth (2012)

10.1002/ART.33392

Erratum: Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors; Association of PPP2CA Polymorphisms With Systemic Lupus Erythematosus Susceptibility in Multiple Ethnic Groups

R. Terkeltaub (2011)

10.1002/art.30520

Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008.

10.1038/nrrheum.2009.236

Update on gout: new therapeutic strategies and options

R. Terkeltaub (2010)

10.1002/acr.20221

Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with Gout

F. Pérez-Ruiz (2010)

10.1007/s00431-011-1530-6

Clinical practice

A. Smeijers (2011)

Association of HLAB*5801 allele and allopurinol-induced stevensjohnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis

R Somkrua (2011)

10.5694/j.1326-5377.1997.tb138701.x

Gout and other crystal arthropathies.

N. McGill (1997)

10.1136/ard.2006.055251

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT)

W. Zhang (2006)

10.1097/FPC.0b013e328330a3b8

Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

W. Tassaneeyakul (2009)

Adherence with urate-lowering therapies for the treatment of gout

L. Harrold (2009)

10.1097/01.rhu.0000164822.98163.22

Correction of Allopurinol Dosing Should Be Based on Clearance of Creatinine, but Not Plasma Creatinine Levels: Another Insight to Allopurinol-Related Toxicity

F. Pérez-Ruiz (2005)

10.1016/j.semarthrit.2010.03.001

Anakinra's efficacy is variable in refractory gout: report of ten cases.

10.1002/art.33483

Developing a provisional definition of flare in patients with established gout.

A. Gaffo (2012)

10.1016/0002-9343(84)90743-5

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

K. Hande (1984)

10.1136/bmj.39449.819271.BE

Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study

10.1056/NEJMOA035700

Purine-rich foods, dairy and protein intake, and the risk of gout in men.

10.1001/jama.2010.1638

Fructose-rich beverages and risk of gout in women.

Soft drinks, fructose consumption, and ACR Guidelines for Gout Management: Part 1 1445 VDA Net srl the risk of gout in men: prospective cohort study

10.1002/acr.21773

2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis

D. Khanna (2012)

Colchicine dosing guidelines for gout patients with varying degrees of renal impairment based on pharmacokinetic data

Soft drinks, fructose consumption, and ACR Guidelines for Gout Management: Part 1 1445 the risk of gout in men: prospective cohort study

10.1136/ard.2008.091462

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout

M. K. Reinders (2009)

10.1097/01.RHU.0000135555.83088.A2

Dosing of antirheumatic drugs in renal disease and dialysis.

A. Swarup (2004)

10.1016/j.amjmed.2010.09.012

Prevalence of contraindications and prescription of pharmacologic therapies for gout.

R. T. Keenan (2011)

A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis : evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy

庄司晃 (2005)

10.1056/NEJMOA050373

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

M. Becker (2005)

10.1002/art.33412

Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.

H. Schumacher (2012)

10.1016/S0140-6736(04)16000-5

Alcohol intake and risk of incident gout in men: a prospective study

10.1001/archinte.168.10.1104

Long-term cardiovascular mortality among middle-aged men with gout.

E. Krishnan (2008)

10.1016/S0190-9622(79)70031-4

The allopurinol hypersensitivity syndrome.

G. Lupton (1979)

kinra ’ s efficacy is variable in refractory gout : report of ten cases

parison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis

JA Alloway (1993)

10.1186/1471-2350-12-118

Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis

Ratchadaporn Somkrua (2011)

10.2165/11535770-000000000-00000

Febuxostat for the Management of Hyperuricaemia in Patients with Gout

M. Stevenson (2012)

10.1177/106002809302700317

Allopurinol Hypersensitivity Syndrome: A Review

F. Arellano (1993)

[Summary of the Dutch College of General Practitioners' "Gout" Standard].

A. Romeijnders (2002)

10.1097/BOR.0b013e328335ef38

A prescription for lifestyle change in patients with hyperuricemia and gout

10.1016/S0140-6736(08)60799-0

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial

Hein J.E.M. Janssens (2008)

10.1185/03007999109111513

Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout.

A. Maccagno (1991)

10.1111/J.1524-4733.2007.00173.X

The impact of gout on work absence and productivity.

N. Kleinman (2007)

American College of Rheumatology Guidelines for Management of Gout Part II: Therapy and Anti-inflammatory Prophylaxis of Acute Gouty Arthritis

D Khanna (2012)

[Summary of the Dutch College of General Practitioners' (NHG) practice guideline 'The menopausal transition'].

C. J. D. de Vries (2012)

10.1111/j.1445-5994.2011.02567.x

Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?

M. H. Lee (2012)

10.1016/J.AMJMED.2006.01.020

Alcohol consumption as a trigger of recurrent gout attacks.

Y. Zhang (2006)

10.1002/ART.22767

Quality of care for gout in the US needs improvement.

J. Singh (2007)

10.1136/ard.2008.099713

Dual energy computed tomography in tophaceous gout

10.1016/j.clinthera.2011.01.008

Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.

R. Wortmann (2010)

10.1592/phco.28.4.437

Comparison of drug adherence rates among patients with seven different medical conditions.

B. Briesacher (2008)

10.1002/art.24209

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

H. Schumacher (2008)

10.1097/MEJ.0b013e32832a083f

Oral prednisolone is more cost-effective than oral indomethacin for treating patients with acute gout-like arthritis

G. Cattermole (2009)

Colchicine dosing guidelines for gout patients with varying degrees of renal impairment based on pharmacokinetic data [abstract

American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis

D Khanna (2012)

Patients with gout adhere to curative treatment if informed appropriately: proof-ofconcept observational study E-pub ahead of print

10.1007/S11926-009-0019-Z

A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout

10.1002/ART.20007

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.

B. Rubin (2004)

An exploratory ultrasound study of early gout.

S. Ottaviani (2011)

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

N. Schlesinger (2011)

10.1002/14651858.CD005521.pub2

Systemic corticosteroids for acute gout.

H. Janssens (2008)

Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide.

C. Fernández (1999)

Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study.

R. Altman (1988)

10.1136/bmj.2.4782.492

Public Health Service

G. Elliston (1952)

American College of Rheumatology recommendations for the use of diseasemodifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

JA Singh (2012)

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis

JM Grossman (2010)

10.1007/s00296-009-1002-8

Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved

R. Thiele (2009)

10.1002/art.1780050406

Long term uricosuric therapy in gout.

G. Thompson (1962)

10.1111/j.1445-5994.1987.tb01232.x

Does colchicine work? The results of the first controlled study in acute gout.

M. Ahern (1987)

10.1002/ART.20102

Quality of care indicators for gout management.

T. Mikuls (2004)

Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis.

J. Alloway (1993)

10.1371/journal.pone.0016780

NSAID Use Selectively Increases the Risk of Non-Fatal Myocardial Infarction: A Systematic Review of Randomised Trials and Observational Studies

L. Garcia Rodriguez (2011)

10.3899/jrheum.090371

Progress in Measurement Instruments for Acute and Chronic Gout Studies

R. Grainger (2009)

A pilot study of IL-1 inhibition by anakinra in acute gout

This paper is referenced by

10.1001/jamadermatol.2018.5336

Screening HLA to Prevent Severe Drug Reactions-A Devil's Advocate Perspective.

S. Divito (2019)

AN INTERDISCIPLINARY OVERVIEW OF START/STOPP CRITERIA IN ELDERLY PATIENTS' DRUG USAGE: A SPECIALIST'S PERSPECTIVE

E. Eksioglu (2016)

10.1007/s40256-020-00400-6

Pharmacologic Management of Gout in Patients with Cardiovascular Disease and Heart Failure

Mallory T. Mouradjian (2020)

10.1007/S15006-014-3487-7

[Update gout: what has changed in diagnosis and treatment?].

Monika Reuss-Borst (2014)

10.1080/20786190.2015.1047148

Update on hyperuricaemia and gout with evidence based management guidelines

Girish M Mody (2015)

10.3109/13813455.2015.1069359

Associations between low levels of serum uric acid and cardiometabolic parameters

Sara Ciarla (2015)

10.1007/S00108-015-0001-Y

Hyperuricemia. When and how to treat

Reuss-Borst Ma (2016)

10.1016/J.MEDCLI.2015.05.009

Hiperuricemia y gota: impacto de la ecografía

Juan García Puig (2016)

10.1177/1524839915614308

Testing an Adapted Modified Delphi Method

Anne L. Escaron (2016)

10.3346/jkms.2014.29.5.657

Prevention of Comorbidity and Acute Attack of Gout by Uric Acid Lowering Therapy

Kowoon Joo (2014)

10.1080/13543776.2017.1261111

An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015)

Ritu Ojha (2017)

10.1016/J.RHUM.2017.09.003

Efficacité et tolérance du fébuxostat chez 73 patients goutteux avec une insuffisance rénale chronique stade 4/5 : étude rétrospective de 10 centres

Pierre-Antoine Juge (2017)

10.5712/RBMFC12(39)1445

Tratamento da Gota na Atenção Primária à Saúde

Flávio Manuel Gomes Guimarães (2017)

10.1007/s10067-018-4243-7

Goals of gout treatment: a patient perspective

J. Singh (2018)

10.1136/annrheumdis-2013-203325

Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative

F. Sivera (2014)

10.1007/s40265-019-01081-5

Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy

M. Gupta (2019)

10.1186/s41065-020-0116-6

Epistatic interaction between PKD2 and ABCG2 influences the pathogenesis of hyperuricemia and gout

10.1186/s41927-019-0056-9

Gout and sexual function: patient perspective of how gout affects personal relationships and intimacy

J. Singh (2019)

10.1097/SMJ.0000000000000082

Hyperuricemia, Gout, and Related Comorbidities: Cause and Effect on a Two-Way Street

E. Karis (2014)

10.1001/jamainternmed.2015.3536

Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.

Chien-Yi Yang (2015)

10.1371/journal.pone.0224272

Variation in methods, results and reporting in electronic health record-based studies evaluating routine care in gout: A systematic review

Samantha S. R. Crossfield (2019)

10.1002/prp2.533

Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers

Keisuke Motoki (2019)

10.1080/14397595.2018.1519149

Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan

Masayuki Hakoda (2018)

10.1177/0897190019866315

Angiotensin Receptor Blockers Effect on Serum Uric Acid-A Class Effect?

Elizabeth M Sutton Burke (2019)

10.1016/J.BERH.2019.03.010

Management of complex gout in clinical practice: Update on therapeutic approaches.

Ravi K. Narang (2018)

10.1016/j.addr.2017.09.011

Two-step polymer- and liposome-enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives.

Anna Scomparin (2017)

10.1007/s10067-019-04737-5

Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial

Zepeng Mu (2019)

10.1155/2020/5603243

Protective Effects and Metabolic Regulatory Mechanisms of Shenyan Fangshuai Recipe on Chronic Kidney Disease in Rats

Xinqi Deng (2020)

10.15416/ijcp.2018.7.1.1

Associations between Obesity, High Purine Consumptions, and Medications on Uric Acid Level with the Use of Allopurinol in Hyperuricemia Patients

Konsumsi Tinggi Purin ()

10.3899/jrheum.190522

Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort

J. Singh (2020)

10.1136/bcr-2015-213601

Coexistent digital gouty and infective flexor tenosynovitis

Q. Akram (2016)

10.1002/14651858.CD006077.pub3

Allopurinol for chronic gout.

Rakhi Seth (2014)

Some data provided by SemanticScholar